Welcome to our dedicated page for Monte Rosa Therapeutics news (Ticker: GLUE), a resource for investors and traders seeking the latest updates and insights on Monte Rosa Therapeutics stock.
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines. The GLUE news page on Stock Titan highlights company announcements that reflect progress across its oncology, immunology, and inflammation programs, as well as its capital markets and collaboration activities.
Investors following Monte Rosa news will see updates on its key clinical candidates, including MRT-2359, a GSPT1-directed MGD being evaluated in MYC-driven solid tumors such as metastatic castration-resistant prostate cancer, and MRT-8102, a NEK7-directed MGD in Phase 1 development for inflammatory diseases driven by the NLRP3 inflammasome, IL-1β, and IL-6. News items also cover MRT-6160, a VAV1-directed MGD for immune-mediated diseases being advanced with Novartis, and preclinical programs targeting cyclin E1 and CDK2.
Typical GLUE news coverage includes clinical trial updates (interim Phase 1 and Phase 1/2 data, study expansions, and planned Phase 2 trials), scientific presentations at major conferences, and collaboration milestones with partners such as Novartis and Roche. Financial and corporate releases, including quarterly results, cash runway commentary, and details of public offerings of common stock and pre-funded warrants, provide additional context on the company’s funding strategy.
By reviewing Monte Rosa’s news feed, readers can track how the company’s QuEEN™ discovery engine is translated into clinical programs, follow the evolution of its MGD pipeline in oncology and immune-mediated diseases, and monitor material events disclosed through press releases that are often cross-referenced in SEC filings. Bookmark this page to access a consolidated view of GLUE-related announcements as they are released.
Summary not available.
Monte Rosa Therapeutics has announced its second development candidate, MRT-6160, a novel molecular glue degrader (MGD) targeting VAV1 for the treatment of autoimmune diseases. The company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024.
Preclinical data show that MRT-6160 potently and selectively degrades VAV1, inhibiting disease progression in autoimmunity models. The molecule acts as an immune modulator, potentially avoiding broad immune suppression seen with other approaches. MRT-6160 is designed to attenuate multiple aspects of T- and B-cell function.
Monte Rosa (Nasdaq: GLUE) aims to develop MRT-6160 as a potential treatment for various autoimmune conditions, particularly those involving T- and B cell-mediated autoimmunity. The company expects it to be their second MGD to enter clinical trials, highlighting the productivity of their QuEEN™ platform.
Summary not available.
Monte Rosa Therapeutics (NASDAQ: GLUE) announced promising preclinical data on MRT-2359, a new orally bioavailable molecular glue degrader targeting MYC-driven tumors, including lung cancer. This data highlights MRT-2359's preferential anti-tumor activity in over 80 patient-derived xenografts, particularly those expressing high levels of N- and L-MYC. As the Phase 1/2 clinical trial (Identifier: NCT05546268) progresses, initial data from the Phase 1 arm is anticipated in late 2023. The trial focuses on evaluating safety, tolerability, and preliminary clinical activity in patients with solid tumors. The findings suggest that MRT-2359 effectively degrades GSPT1, disrupting protein synthesis and inhibiting MYC target gene expression. Monte Rosa aims to leverage its QuEEN™ platform to further enhance GSPT1 degradation and advance cancer treatment.
BOSTON, March 23, 2023 — Monte Rosa Therapeutics (NASDAQ: GLUE) announced the appointment of Jan Skvarka, Ph.D., MBA, to its Board of Directors. Dr. Skvarka brings over 30 years of experience in biopharmaceuticals, including leadership roles in clinical-stage companies. His tenure includes transforming Trillium Therapeutics from a $16 million market cap to a $2.3 billion acquisition by Pfizer within two years. Monte Rosa emphasizes its commitment to developing innovative molecular glue degrader medicines targeting serious diseases, leveraging its QuEEN™ platform. This appointment is viewed as a strategic move to advance its clinical and corporate objectives.
Monte Rosa Therapeutics (NASDAQ: GLUE) reported its fourth quarter and full year 2022 financial results, highlighting a net loss of $30.8 million in Q4 2022 and $108.5 million for the year. R&D expenses rose to $24.9 million for Q4 2022, driven by advancements in their MRT-2359 clinical trial for MYC-driven tumors, which received Fast Track designation from the FDA. The company ended 2022 with a cash balance of approximately $268 million, ensuring operational funding into 2025. Upcoming milestones include initial clinical data disclosure for MRT-2359 expected in late 2023 and nomination of development candidates from their various therapeutic programs.
BOSTON, Feb. 3, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (NASDAQ: GLUE) is set to participate in several investor events, showcasing its advancements in molecular glue degrader (MGD) therapies. Key events include:
- Guggenheim Oncology Conference on February 9, 2023, at 2:45 p.m. ET
- BMO Virtual Biopharma Spotlight on February 10, 2023, at 10:00 a.m. ET
- SVB Securities Global Biopharma Conference on February 14, 2023, at 11:20 a.m. ET
- Wells Fargo Targeted Protein Degradation Summit on February 21, 2023, at 3:00 p.m. ET
- Cowen’s 43rd Annual Health Care Conference on March 7, 2023, at 10:30 a.m. ET
Webcasts will be available on the company's investor site.
Monte Rosa Therapeutics (NASDAQ: GLUE) announced key milestones for 2023, including FDA's Fast Track designation for MRT-2359 aimed at treating previously treated, metastatic non-small cell lung cancer (NSCLC) expressing L-MYC or N-MYC. Initial data from the ongoing Phase 1/2 trial is expected in H2 2023, alongside the nomination of additional development candidates. The company will present updates at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023.
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (NASDAQ: GLUE), a biotechnology company focused on novel molecular glue degrader (MGD)-based medicines, announced that CEO Markus Warmuth is set to present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 11:15 a.m. PT. The presentation will be accessible via the company’s investor site, with an archived version available for 90 days.
Monte Rosa's innovative approach utilizes a proprietary platform called QuEEN™ to identify therapeutic protein targets for drug development.
Monte Rosa Therapeutics (GLUE) announced significant advancements in its clinical programs, including the initiation of patient dosing for MRT-2359, a GSPT1-directed molecular glue degrader targeting MYC-driven tumors. The company reported a net loss of $27.3 million for Q3 2022, up from $19.8 million in Q3 2021. R&D expenses rose to $21.3 million due to expanded activities in MRT-2359 and the QuEEN™ platform. As of September 30, 2022, Monte Rosa maintains a cash position of $277.4 million, expected to support operations until late 2024.